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1. SELECTION OF MODEL CPPs 
Based on: 
• Chemically different groups of CPPs in chemical space (see figure introduction) 
• CP-response 
 
 
 
 
 
 
2. IN VITRO METABOLIC STABILITY OF CPPs 
 
 
 
 
 
 
 
 
 
 
3. IN VIVO BLOOD-BRAIN BARRIER TRANSPORT STUDY 
a. Blood-to-brain transport (MTR) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
•  A homogenous distribution to the three main brain regions was observed 
for pVEC, transportan 10 and TP10-2. 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
b. Capillary and parenchymal distribution 
 
 
 
 
 
 
 
 
 
 
 
 
c. Brain-to-blood transport (efflux) 
 
 
 
 
 
 
 
 
 
Good cell-penetrating properties of peptides are not a guarantee for blood-brain barrier penetrating ability. 
Drug Quality & Registration (DruQuaR) format man06.001.003-v02 
INTRODUCTION  
EXPERIMENTAL 
RESULTS and DISCUSSION  
CONCLUSION 
REFERENCES 
DruQuaR 
• Cell-penetrating peptides (CPPs) are a chemically diverse group of peptides and show diverse 
cell-penetrating (CP) responses, which express their cell-penetrating ability [1]. 
• In literature, a limited number of studies are available describing CPP-mediated improved 
transport of different therapeutic molecules across the blood-brain barrier (BBB) in vivo. 
• Quantitative BBB transport data of uncoupled CPPs are currently lacking.  
 
 Do all CPPs cross the BBB? 
a. Blood-to-brain transport:  
Multiple time regression (MTR) study after IV injection 
b. Capillary and parenchymal distribution:  
Capillary depletion study after IV injection 
c. Brain-to-blood transport:  
Efflux study after intracerebroventricular injection 
1. Selection of model CPPs 
2. In vitro metabolic stability of CPPs in mouse serum and mouse liver,       
kidney and brain homogenates 
3. In vivo blood-brain barrier transport study using ICR CD-1 mice: 
 
Peptide 
Half life (min) 
Serum Liver Kidneys Brain 
Tat 47-57 3 60 18 54 
SynB3 6 37 5 21 
pVEC < 3 43 7 68 
Transportan 10 1316 139 34 176 
TP10-2 229 118 11 102 
Selected peptide CP-response Chemical class (cluster) 
Tat 47-57 0.31 Cationic (light blue) 
SynB3 0.13 Cationic (light blue) 
pVEC 1.32 Amphipathic-cationic (yellow) 
Transportan 10 1.64 Amphipathic-cationic (pink) 
TP10-2 0.75 Amphipathic-cationic (pink) 
Arginine-
rich 
Lysine-
rich 
Lower serum stability of arginine-rich CPPs 
High 
CPP 
Low 
CPP 
• pVEC shows 
extraordinary high influx 
into brain. 
 
• SynB3 and Tat 47-57 
show a high brain influx. 
 
• Transportan 10 and 
TP10-2 have a low to 
very low brain influx.  
Resp. positive and negative control.  
± 80% of the peptide 
amount that crossed 
the BBB entered the 
brain parenchyma. 
Peptide kout (min
-1) 
Tat 47-57 0.21 ± 0.08 
SynB3 0.05 ± 0.01 
pVEC 0.10 ± 0.11  
Transportan 10 0.09 ± 0.02 
TP10-2 0.06 ± 0.01 
pVEC: no statistically 
significant efflux 
 Brain cortex 
 Cerebellum  
(= cerebellum + pons + medulla oblongata) 
 Midbrain  
(= hippocampus + striatum + (hypo)thalamus + 
basal forebrain + midbrain) 
 Sum of brain regions 
 
